Moors & Cabot Inc. Sells 22,061 Shares of Qiagen N.V. $QGEN

Moors & Cabot Inc. reduced its stake in shares of Qiagen N.V. (NYSE:QGEN) by 6.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 330,748 shares of the company’s stock after selling 22,061 shares during the quarter. Moors & Cabot Inc.’s holdings in Qiagen were worth $14,874,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA increased its holdings in shares of Qiagen by 1.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,205,881 shares of the company’s stock worth $1,088,538,000 after purchasing an additional 264,921 shares during the period. Vanguard Group Inc. increased its stake in Qiagen by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock valued at $433,871,000 after acquiring an additional 118,135 shares during the period. Amundi raised its holdings in Qiagen by 4.4% in the 3rd quarter. Amundi now owns 4,290,273 shares of the company’s stock valued at $201,471,000 after acquiring an additional 181,509 shares in the last quarter. Boston Partners acquired a new position in Qiagen in the 3rd quarter valued at approximately $179,450,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Qiagen by 10.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 3,164,805 shares of the company’s stock worth $143,018,000 after acquiring an additional 290,449 shares during the period. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Price Performance

Shares of QGEN stock opened at $36.65 on Friday. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81. The firm has a fifty day moving average of $37.76 and a 200-day moving average of $44.80. The firm has a market capitalization of $7.55 billion, a price-to-earnings ratio of 19.14, a price-to-earnings-growth ratio of 3.59 and a beta of 0.64.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.54 EPS for the quarter, hitting the consensus estimate of $0.54. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The business had revenue of $492.32 million for the quarter, compared to the consensus estimate of $496.15 million. During the same quarter last year, the business posted $0.56 EPS. On average, equities research analysts forecast that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th will be issued a dividend of $0.35 per share. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date is Tuesday, July 7th. This represents a dividend yield of 104.0%. Qiagen’s dividend payout ratio (DPR) is presently 13.61%.

Wall Street Analyst Weigh In

QGEN has been the topic of several recent research reports. Robert W. Baird set a $43.00 price objective on Qiagen and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Zacks Research raised Qiagen from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 29th. Jefferies Financial Group reiterated a “buy” rating and set a $59.00 price target on shares of Qiagen in a research note on Thursday, February 5th. Weiss Ratings cut shares of Qiagen from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, May 12th. Finally, Barclays set a $38.00 price objective on shares of Qiagen and gave the stock an “equal weight” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.98.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: QIAGEN announced two custom RUO digital PCR assays to support research and surveillance efforts tied to the Bundibugyo ebolavirus outbreak, reinforcing demand for its QIAcuity digital PCR platform and its role in infectious-disease monitoring. Article Title
• Positive Sentiment: A Zacks commentary pointed to longer-term growth drivers for QIAGEN, including new product launches, automation via Connect, and expansion of the QIAstat-Dx menu, suggesting the company is working to stabilize growth through 2027. Article Title
• Neutral Sentiment: Qiagen’s second-quarter and multi-year earnings estimates were trimmed by Zacks Research, but the firm kept a Hold rating and still sees earnings growth over the next several years. Article Title
• Neutral Sentiment: Pomerantz LLP said it is investigating claims on behalf of Qiagen investors, which adds legal uncertainty but does not yet indicate a formal lawsuit or financial impact. Article Title
• Negative Sentiment: Multiple Zacks Research updates lowered earnings forecasts for FY2026, FY2027, FY2028 and several quarterly periods, signaling some concern about near-term profitability and tempering enthusiasm for the stock. Article Title

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.